FDA Clears PET-Based Software for Centiloid Scaling of Amyloid Plaque Density
Now available with MIMneuro, the Centiloid scaling software provides automated quantitative assessment of amyloid plaque density, a key component of Alzheimer’s disease.
The Food and Drug Administration (FDA) has granted 510(k) clearance to new Centiloid scaling software that enhances the assessment of amyloid plaque density on positron emission tomography (PET) and may facilitate the use of amyloid-targeted therapies for patients with Alzheimer’s disease.
Through the assessment of PET amyloid imaging, the Centiloid scaling software reportedly provides automated quantitative information on amyloid plaque density, according to MIM Software/GE HealthCare, the developer of the software. The company emphasized that amyloid plaque density is a key component of Alzheimer’s disease.
Through the assessment of PET amyloid imaging, the newly FDA-cleared Centiloid scaling software reportedly provides automated quantitative information on amyloid plaque density, according to MIM Software/GE HealthCare, the developer of the software. (Image courtesy of MIM Software/GE HealthCare.)
MIM Software said the Centiloid scaling software, now available with MIMneuro, also facilitates workflow efficiency by providing the quantitative assessments of amyloid plaque density alongside the PET images in a standardized report.
“Alzheimer’s is a far-reaching disease that has been a challenge for our society, patients, caregivers, and healthcare systems for decades,” explains Andrew Nelson, CEO of MIM Software, GE HealthCare. “Centiloid scaling with MIMneuro offers a standardized, quantitative metric to assist healthcare providers in confidently estimating amyloid plaque density, one key aspect of this debilitating disease. By increasing clinician confidence, we hope to ultimately expand patient access to cutting-edge, personalized care.”
Recent Videos
Related Content
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Article
Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025Podcast
In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025Article
The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025Article
For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025Article
For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
